Quick Answer
4D Molecular Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $85.21 million for the year ending 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +230,194.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from 4D Molecular Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), 4D Molecular Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 1,124.3%.
- Historical annual values: Fiscal year 2025: $85.21 million | Fiscal year 2024: $37.0 thousand | Fiscal year 2023: $20.72 million | Fiscal year 2022: $3.13 million | Fiscal year 2021: $18.04 million | Fiscal year 2020: $13.36 million | Fiscal year 2019: $6.96 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: